Endpoints
The Endpoints Podcast features guests from the ALS community, including people living with ALS, researchers, advocates and fundraisers. Each episode cuts to the chase with short, digestible conversations about the latest research at ALS TDI and the most closely watched ALS clinical trials as well as stories from people living with ALS with their thoughts on research, healthcare and their journey with ALS.
The Endpoints Podcast is hosted by the ALS Therapy Development Institute (ALS TDI) the world's foremost drug discovery lab focused solely on ALS. ALS TDI is a non-profit biotech with one mission. End ALS.
To access all episodes of the Endpoints Podcast, visit als.net/endpoints.
- Update frequency
- every 18 days
- Average duration
- 18 minutes
- Episodes
- 67
- Years Active
- 2019 - 2025
Collin Hadley: Choosing to use Mechanical Ventilation for ALS
In this episode of the Endpoints, Collin Hadley joins Gabrielle Bellitti, Outreach and Engagement Specialist at ALS TDI, to talk about living with ALS and using mechanical ventilation. Collin discuss…
Samantha Van Saun: Building an ALS Community
In this episode of the Endpoints Podcast, Dileep Dadlani, Development Director at ALS TDI is joined by Samantha Van Saun who is a Champion in ALS TDI’s ALS Community in Richmond, VA. Samantha has los…
NurOwn and the Hope for Stem Cells in ALS?
On this episode of the Endpoints, Dr. Steve Perrin, CEO at ALS TDI answers questions about one of the most talked about clinical trials in ALS at the moment, Brainstorm Cell Therapeutics’ NurOwn, a p…
Tamara Hillard: Anticipating Needs as an ALS Caregiver
In this episode of the Endpoints, Tamara Hilliard, from Fort Worth, Texas, talks about the challenges of caring for her husband, Jim, who’s living with ALS, and his anticipated needs ahead of time. …
Jeff Roosa: Uniting First Responders to End ALS
In this episode of the Endpoints, Jeff Roosa, Lee, MA Chief of Police, joins Gabrielle Bellitti, Outreach and Engagement Specialist at ALS TDI, to talk about living with ALS and uniting first respond…
What to know about CuATSM clinical trials
In this episode, Dr. Fernando Vieira, CSO at the ALS Therapy Development Institute (ALS TDI), joins us to discuss Copper ATSM (CuATSM)clinical trials. CuATSM is a small molecule drug sponsored by the…
What Do We Know About C9ORF72?
In this episode of the Endpoints, Dr. Fernando Vieira explains what we know so far about C9ORF72, a gene which has been implicated in up to 40% of cases of familial ALS. C9ORF72was discovered to be a…